“Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s49. doi:10.25251/skin.4.supp.48.